Literature DB >> 24684593

The role of thiopurine metabolite monitoring in inflammatory bowel disease.

Lauren Beswick1, Antony B Friedman, Miles P Sparrow.   

Abstract

Thiopurines are the mainstay of medical management in inflammatory bowel disease (IBD), especially in the maintenance of disease remission. Given the limited IBD armamentarium it is important to optimize each therapy before switching to an alternative drug. Conventional weight based dosing of thiopurines in IBD leads to intolerance or inefficacy in many patients. More recently increased knowledge of their metabolism has allowed for dose optimization using thiopurine metabolite levels, namely 6-thioguanine nucleotides and 6-methylmercaptopurine, with the potential for improved outcomes in patients with IBD. This review will outline the current understanding of thiopurine metabolism and pharmacogenomics and will describe the clinical application of this knowledge in the optimization of thiopurines in individual patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684593     DOI: 10.1586/17474124.2014.894878

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  5 in total

1.  Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilization in Singapore.

Authors:  Jia Qi Yeo; Hua Heng McVin Cheen; Amanda Wong; Teong Guan Lim; Balram Chowbay; Wai Fook Leong; Chunyan Wang; Ennaliza Salazar; Webber Pak Wo Chan; San Choon Kong; Wan Chee Ong
Journal:  JGH Open       Date:  2022-08-01

2.  Reversal of intestinal failure-associated liver disease (IFALD): emphasis on its multifactorial nature.

Authors:  Christian Hvas; Kamelia Kodjabashia; Emma Nixon; Stephen Hayes; Kirstine Farrer; Arun Abraham; Simon Lal
Journal:  Frontline Gastroenterol       Date:  2015-04-09

3.  Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.

Authors:  Melek Simsek; Debbie S Deben; Carmen S Horjus; Melanie V Bénard; Birgit I Lissenberg-Witte; Hans J C Buiter; Matthijs van Luin; Margien L Seinen; Chris J J Mulder; Dennis R Wong; Nanne K H de Boer; Adriaan A van Bodegraven
Journal:  Aliment Pharmacol Ther       Date:  2019-05-16       Impact factor: 8.171

4.  Thiopurine metabolite level and toxicity in Indians with inflammatory bowel disease.

Authors:  Suruchi P Parkar; Alpa J Dherai; Devendra C Desai; Tester F Ashavaid
Journal:  JGH Open       Date:  2017-09-18

Review 5.  Use of thiopurines in inflammatory bowel disease: an update.

Authors:  Arshdeep Singh; Ramit Mahajan; Saurabh Kedia; Amit Kumar Dutta; Abhinav Anand; Charles N Bernstein; Devendra Desai; C Ganesh Pai; Govind Makharia; Harsh Vardhan Tevethia; Joyce Wy Mak; Kirandeep Kaur; Kiran Peddi; Mukesh Kumar Ranjan; Perttu Arkkila; Rakesh Kochhar; Rupa Banerjee; Saroj Kant Sinha; Siew Chien Ng; Stephen Hanauer; Suhang Verma; Usha Dutta; Vandana Midha; Varun Mehta; Vineet Ahuja; Ajit Sood
Journal:  Intest Res       Date:  2021-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.